ASSAY and Drug Development Technologies is pleased to announce an upcoming special issue on the impactful topic of inducible pluripotent-derived neuroprogenitor cells (iPS NPCs). These cells have transformed drug discovery efforts by providing neurologically relevant cell-based populations for assay development and high throughput screening. Recent studies have supported the critical inroads that iPS NPCs and resulting neurons have had in drug discovery suggesting these cell populations may help bridge the translational research gap. Thus, iPS NPCs and derived neurons could potentially revolutionize the assay and screening models used in drug discovery for a range of brain-targeted diseases. We are seeking impactful research on the following topics: 

• iPS NPC/neuron-based model systems used in assay development and validation
• High throughput and high content screening using iPS NPC/neuron-based model systems
• Development or use of iPS-derived “mini-brains” in drug discovery
• Derivation and use of novel patient-derived iPS NPC lines for drug screening

Advantages of publishing in ASSAY and Drug Development Technologies include:

• Fast and user-friendly electronic submission
• Rapid, high quality peer-review
• Maximum exposure: accessible in 170 countries worldwide
• Open Access options available
• Competitive author benefits program

About the Journal

ASSAY and Drug Development Technologies delivers access to the techniques and tools that enable new advances in early-stage screening, and lead to therapeutic compounds for drug discovery and development. This authoritative, rapidly peer-reviewed journal features original papers, application-oriented technology reviews, and reports in methodology and technology applications. The Journal is under the leadership of Bruce Melancon, PhD, University of Notre Dame.

The Journal also features a dedicated Drug Repurposing, Rescue, and Repositioning (DRRR) section. These special peer-reviewed collections of papers present techniques and tools for finding new uses for approved drugs – particularly for disorders where no animal model, physiologic abnormality, biochemical pathway, or molecular target has been identified. The DRRR section is under the leadership of Hermann Mucke, PhD, of Hermann Mucke Pharma Consultancy e.U.